Glycerol 85% efficacy on atopic skin and its microbiome: A Randomized Controlled Trial with Clinical and Bacteriological Evaluation.

Clicks: 372
ID: 73303
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 5 articles by views in the journal of dermatological treatment

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Treating atopic dermatitis (AD) is still a challenge. The staphylococcal skin load is known to aggravate AD. Narrow band ultraviolet B (NB-UVB) and glycerol in low concentration (20-40%) are established therapies for AD. NB-UVB has proven antimicrobial actions, while high concentration glycerol (85-100%) showed similar effects in vitro but hasn't been clinically tested. To evaluate the efficacy and tolerability of concentrated glycerol 85% compared to NB-UVB in patients with AD, as assessed by clinical improvement and reduction of staphylococcal colonization of the skin. 30 patients with mild to moderate AD were randomized into either nb-uvb or glycerol 85% group. Patients were treated for one month and followed for an additional month. Swabs were taken from the skin and nose to be cultured on mannitol-salt agar for Staphylococci and quantified to determine Colony Forming Units (CFU). Both groups showed statistically insignificant microbial changes and statistically significant clinical improvement after treatment. The results were comparable between both groups. Concentrated glycerol 85% is a cheap effective readily accessible alternative for phototherapy in patients with mild-moderate AD who cannot access the facility. Reduction of staphylococcal skin load seems to be involved, but its role is minimal. Pan African Clinical Trial Registry (www.pactr.org) PACTR201810815694251.
Reference Key
youssef2019glycerolthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Youssef, R;Hafez, V;Elkholy, Y;Mourad, A;
Journal the journal of dermatological treatment
Year 2019
DOI
10.1080/09546634.2019.1708246
URL
Keywords
glycerol atopic dermatitis microbiome staphylococcus phototherapy ultraviolet therapy glycerol atopic dermatitis microbiome staphylococcus phototherapy ultraviolet therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.